These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 17348107)

  • 21. Negative phase 3 randomized controlled trials: Why cancer drugs fail the last barrier?
    Gyawali B; Addeo A
    Int J Cancer; 2018 Oct; 143(8):2079-2081. PubMed ID: 29744864
    [No Abstract]   [Full Text] [Related]  

  • 22. Trial watch: pivotal oncology trials: outlook for Q2 2009.
    Nehring R
    Nat Rev Drug Discov; 2009 Apr; 8(4):266. PubMed ID: 19337264
    [No Abstract]   [Full Text] [Related]  

  • 23. Getting across the phase III finish line.
    Scudellari M
    Cancer Discov; 2013 Apr; 3(4):370. PubMed ID: 23580269
    [No Abstract]   [Full Text] [Related]  

  • 24. [Phase III study].
    Furuse K
    Gan To Kagaku Ryoho; 1995 Apr; 22(5):611-5. PubMed ID: 7717712
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Taking stock of targeted therapy in cancer: rational expectations or irrational exuberance?
    Edelman MJ
    Expert Rev Anticancer Ther; 2003 Apr; 3(2):127-9. PubMed ID: 12722869
    [No Abstract]   [Full Text] [Related]  

  • 26. [Glaxo Smith Kline. A large oncology pipeline].
    Med Monatsschr Pharm; 2006 Oct; 29(10):385-6. PubMed ID: 17058903
    [No Abstract]   [Full Text] [Related]  

  • 27. Requiring institutions to inform participants who have completed therapy on SWOG-8892 (RT +/- cisplatin for nasopharyngeal cancer) about early study closure: right idea, wrong patients.
    Amdur RJ; Bankert E
    Int J Radiat Oncol Biol Phys; 1997 Jun; 38(3):673. PubMed ID: 9231694
    [No Abstract]   [Full Text] [Related]  

  • 28. Studies at ASCO report results on new drug therapies and survivorship issues.
    Printz C
    Cancer; 2011 Aug; 117(16):3629. PubMed ID: 21815132
    [No Abstract]   [Full Text] [Related]  

  • 29. Time to mandate data release and independent audits for all clinical trials.
    Haines IE; Gabor Miklos GL
    Med J Aust; 2011 Nov; 195(10):575-7. PubMed ID: 22106997
    [No Abstract]   [Full Text] [Related]  

  • 30. [Status quo and problems in phase III trials: view of a trialist].
    Hamajima N
    Gan To Kagaku Ryoho; 1995 Feb; 22(3):319-22. PubMed ID: 7880101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology.
    Ji Y; Jin JY; Hyman DM; Kim G; Suri A
    Clin Transl Sci; 2018 Jul; 11(4):345-351. PubMed ID: 29392871
    [No Abstract]   [Full Text] [Related]  

  • 32. Multi-arm clinical trials of new agents: some design considerations.
    Freidlin B; Korn EL; Gray R; Martin A
    Clin Cancer Res; 2008 Jul; 14(14):4368-71. PubMed ID: 18628449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patupilone in cancer treatment.
    Bystricky B; Chau I
    Expert Opin Investig Drugs; 2011 Jan; 20(1):107-17. PubMed ID: 21142807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecule of the month. Temsirolimus.
    Drug News Perspect; 2007; 20(6):406. PubMed ID: 17925894
    [No Abstract]   [Full Text] [Related]  

  • 35. The fight against cancer: the next round.
    Doherty M
    Drug Discov Today; 2004 Nov; 9(22):947-8. PubMed ID: 15539135
    [No Abstract]   [Full Text] [Related]  

  • 36. New scale assesses benefits of cancer medicines.
    Bagcchi S
    Lancet Oncol; 2015 Jul; 16(7):e316. PubMed ID: 26051234
    [No Abstract]   [Full Text] [Related]  

  • 37. Innovative antineoplastic agents.
    Wood L
    J Intraven Nurs; 2001; 24(1):48-55. PubMed ID: 11836844
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Failures in Phase III: Causes and Consequences.
    Seruga B; Ocana A; Amir E; Tannock IF
    Clin Cancer Res; 2015 Oct; 21(20):4552-60. PubMed ID: 26473191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deal watch: Bristol-Myers Squibb and Exelixis collaborate on kinase inhibitors.
    Nat Rev Drug Discov; 2009 Feb; 8(2):98. PubMed ID: 19180098
    [No Abstract]   [Full Text] [Related]  

  • 40. General and statistical hierarchy of appropriate biologic endpoints.
    Sargent D
    Oncology (Williston Park); 2006 May; 20(6 Suppl 5):5-9. PubMed ID: 16773839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.